SK6392003A3 - Novel uses of combined selective dopamine D2 receptor antagonists and 5-HT1A receptor agonists - Google Patents

Novel uses of combined selective dopamine D2 receptor antagonists and 5-HT1A receptor agonists Download PDF

Info

Publication number: SK6392003A3
Authority: SK; Slovakia
Prior art keywords: physiologically acceptable; receptor; acceptable salt; treatment; selective dopamine
Prior art date: 2000-11-14

Application number

SK639-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Gerd Bartoszyk

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-14

Filing date

2001-10-25

Publication date

2003-11-04

2001-10-25 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2003-11-04 Publication of SK6392003A3 publication Critical patent/SK6392003A3/sk

Links

239000000018 receptor agonist Substances 0.000 title abstract description 14
229940044601 receptor agonist Drugs 0.000 title abstract description 14
229940123603 Dopamine D2 receptor antagonist Drugs 0.000 title abstract description 13
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 title abstract description 6
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 title abstract description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 37
238000011282 treatment Methods 0.000 abstract description 28
239000003814 drug Substances 0.000 abstract description 26
150000003839 salts Chemical class 0.000 abstract description 25
150000001875 compounds Chemical class 0.000 abstract description 19
238000004519 manufacturing process Methods 0.000 abstract description 11
230000000472 traumatic effect Effects 0.000 abstract description 11
208000019901 Anxiety disease Diseases 0.000 abstract description 9
230000003542 behavioural effect Effects 0.000 abstract description 8
208000035475 disorder Diseases 0.000 description 34
230000006399 behavior Effects 0.000 description 27
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 26
-1 cyanophenoxyethyl Chemical group 0.000 description 20
241001465754 Metazoa Species 0.000 description 19
241000282472 Canis lupus familiaris Species 0.000 description 12
241000271566 Aves Species 0.000 description 11
150000001412 amines Chemical class 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
241000282326 Felis catus Species 0.000 description 10
201000004624 Dermatitis Diseases 0.000 description 8
241000283086 Equidae Species 0.000 description 8
208000027418 Wounds and injury Diseases 0.000 description 8
230000006378 damage Effects 0.000 description 8
201000004384 Alopecia Diseases 0.000 description 7
230000001107 psychogenic effect Effects 0.000 description 7
230000001154 acute effect Effects 0.000 description 6
210000003746 feather Anatomy 0.000 description 6
208000014674 injury Diseases 0.000 description 6
239000000902 placebo Substances 0.000 description 6
229940068196 placebo Drugs 0.000 description 6
231100000360 alopecia Toxicity 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
206010052813 Aerophagia Diseases 0.000 description 4
208000037071 Aerophagy Diseases 0.000 description 4
241000287530 Psittaciformes Species 0.000 description 4
230000036506 anxiety Effects 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
HKFMQJUJWSFOLY-OAQYLSRUSA-N sarizotan Chemical compound C1=CC(F)=CC=C1C1=CN=CC(CNC[C@@H]2OC3=CC=CC=C3CC2)=C1 HKFMQJUJWSFOLY-OAQYLSRUSA-N 0.000 description 4
241000894007 species Species 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 3
239000000442 dopamine 2 receptor blocking agent Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
230000004044 response Effects 0.000 description 3
229940076279 serotonin Drugs 0.000 description 3
239000000952 serotonin receptor agonist Substances 0.000 description 3
206010018691 Granuloma Diseases 0.000 description 2
206010057342 Onychophagia Diseases 0.000 description 2
241000287531 Psittacidae Species 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
239000000556 agonist Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
206010008118 cerebral infarction Diseases 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
210000003414 extremity Anatomy 0.000 description 2
230000003676 hair loss Effects 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000006748 scratching Methods 0.000 description 2
230000002393 scratching effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
FGBFEFJZYZDLSZ-UHFFFAOYSA-N 5,7-dimethoxy-2,3-dimethyl-2,3-dihydroinden-1-one Chemical compound COC1=CC(OC)=CC2=C1C(=O)C(C)C2C FGBFEFJZYZDLSZ-UHFFFAOYSA-N 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
206010000599 Acromegaly Diseases 0.000 description 1
206010001488 Aggression Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010001928 Amenorrhoea Diseases 0.000 description 1
241000287523 Ara Species 0.000 description 1
241000726096 Aratinga Species 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
241000282465 Canis Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
241000269333 Caudata Species 0.000 description 1
208000018152 Cerebral disease Diseases 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241000167880 Hirundinidae Species 0.000 description 1
101000629937 Homo sapiens Translocon-associated protein subunit alpha Proteins 0.000 description 1
208000035154 Hyperesthesia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010058359 Hypogonadism Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000865978 Loriculus Species 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
AZZJIWTWPVUAEW-JOCHJYFZSA-N O1[C@H](CCC2=CC=CC=C12)C(=O)OCNCC=1C=NC=C(C1)C1=CC=C(C=C1)F Chemical class O1[C@H](CCC2=CC=CC=C12)C(=O)OCNCC=1C=NC=C(C1)C1=CC=C(C=C1)F AZZJIWTWPVUAEW-JOCHJYFZSA-N 0.000 description 1
206010031252 Osteomyelitis Diseases 0.000 description 1
206010031253 Osteomyelitis acute Diseases 0.000 description 1
206010031256 Osteomyelitis chronic Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
241000665182 Pezoporus occidentalis Species 0.000 description 1
206010036618 Premenstrual syndrome Diseases 0.000 description 1
241000287520 Psittacula Species 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
208000004188 Tooth Wear Diseases 0.000 description 1
102100026231 Translocon-associated protein subunit alpha Human genes 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
231100000871 behavioral problem Toxicity 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
150000003938 benzyl alcohols Chemical class 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
229960001564 clomipramine hydrochloride Drugs 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
231100000867 compulsive behavior Toxicity 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000002950 deficient Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000003210 dopamine receptor blocking agent Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000005553 drilling Methods 0.000 description 1
239000006196 drop Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
229960003133 ergot alkaloid Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
206010016766 flatulence Diseases 0.000 description 1
229960002464 fluoxetine Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
230000035929 gnawing Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
210000000003 hoof Anatomy 0.000 description 1
230000002631 hypothermal effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000006651 lactation Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
244000144972 livestock Species 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
208000019180 nutritional disease Diseases 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000001603 reducing effect Effects 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
239000013005 self healing agent Substances 0.000 description 1
239000003723 serotonin 1A agonist Substances 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
210000000779 thoracic wall Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000009941 weaving Methods 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Gynecology & Obstetrics (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pregnancy & Childbirth (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)

SK639-2003A 2000-11-14 2001-10-25 Novel uses of combined selective dopamine D2 receptor antagonists and 5-HT1A receptor agonists SK6392003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00124814		2000-11-14
PCT/EP2001/012325 WO2002039988A2 (fr)	2000-11-14	2001-10-25	Nouvelles utilisations de l'antagoniste combines selectif du recepteur d2 de la dopamine et de l'agoniste du recepteur de la 5-ht¿1a?

Publications (1)

Publication Number	Publication Date
SK6392003A3 true SK6392003A3 (en)	2003-11-04

Family

ID=8170368

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK639-2003A SK6392003A3 (en)	2000-11-14	2001-10-25	Novel uses of combined selective dopamine D2 receptor antagonists and 5-HT1A receptor agonists

Country Status (18)

Country	Link
US (1)	US20040014788A1 (fr)
EP (1)	EP1333821A2 (fr)
JP (1)	JP2004513915A (fr)
KR (1)	KR20030065511A (fr)
CN (1)	CN1474688A (fr)
AR (1)	AR035503A1 (fr)
AU (1)	AU2002221744A1 (fr)
BR (1)	BR0115297A (fr)
CA (1)	CA2428519A1 (fr)
CZ (1)	CZ20031434A3 (fr)
HU (1)	HUP0302761A2 (fr)
MX (1)	MXPA03004249A (fr)
NO (1)	NO20032149D0 (fr)
PL (1)	PL361462A1 (fr)
RU (1)	RU2283648C2 (fr)
SK (1)	SK6392003A3 (fr)
WO (1)	WO2002039988A2 (fr)
ZA (1)	ZA200304602B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL2009131C2 (en) *	2012-07-05	2014-01-07	Stichting Vu Vumc	Compound and use of compound to prepare a radiollabelled compound.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69123090D1 (de) *	1990-07-06	1996-12-19	Yoshitomi Pharmaceutical	Kondensierte Thiophenverbindungen und deren Verwendung
US5314888A (en) *	1992-02-21	1994-05-24	Trustees Of Tufts College	Veterinary method for treating inappropriate elimination of urine in household pets
GB9302622D0 (en) *	1993-02-10	1993-03-24	Wellcome Found	Heteroaromatic compounds
ZA954688B (en) *	1994-06-08	1996-01-29	Lundbeck & Co As H	Serotonin 5-HT1A and dopamin D2 receptor ligands
ATE210657T1 (de) *	1994-10-14	2001-12-15	Merck Patent Gmbh	Zns wirksames (r)-(-)-2-(5-(4-fluorophenyl)-3- pyridylmethylaminomethyl)chroman
US5554383A (en) *	1995-04-06	1996-09-10	Trustees Of Tufts College	Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
AU6517196A (en) *	1995-07-13	1997-02-10	Knoll Aktiengesellschaft	Piperazine derivatives as therapeutic agents
GB9514380D0 (en) *	1995-07-13	1995-09-13	Knoll Ag	Therapeutic agents
ATE253058T1 (de) *	1997-09-02	2003-11-15	Duphar Int Res	Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
EP0900792B1 (fr) *	1997-09-02	2003-10-29	Duphar International Research B.V	Dérivés de pipéridine et de pipérazine comme agonistes du récepteur 5-HT1
AU2981099A (en) *	1998-03-09	1999-09-27	Trustees Of Tufts College	Treatment of compulsive behaviours in man and animals
AR015036A1 (es) *	1998-04-29	2001-04-11	American Home Prod	Derivados de indolilo antisicoticos, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento
UA71590C2 (en) *	1998-11-13	2004-12-15	Duphar Int Res	Piperazine and piperidine derivatives

2001
- 2001-10-25 WO PCT/EP2001/012325 patent/WO2002039988A2/fr not_active Application Discontinuation
- 2001-10-25 KR KR10-2003-7006474A patent/KR20030065511A/ko not_active Ceased
- 2001-10-25 PL PL01361462A patent/PL361462A1/xx unknown
- 2001-10-25 HU HU0302761A patent/HUP0302761A2/hu unknown
- 2001-10-25 JP JP2002542363A patent/JP2004513915A/ja active Pending
- 2001-10-25 BR BR0115297-1A patent/BR0115297A/pt not_active IP Right Cessation
- 2001-10-25 AU AU2002221744A patent/AU2002221744A1/en not_active Abandoned
- 2001-10-25 RU RU2003115433/15A patent/RU2283648C2/ru not_active IP Right Cessation
- 2001-10-25 MX MXPA03004249A patent/MXPA03004249A/es not_active Application Discontinuation
- 2001-10-25 US US10/416,575 patent/US20040014788A1/en not_active Abandoned
- 2001-10-25 CN CNA018188222A patent/CN1474688A/zh active Pending
- 2001-10-25 SK SK639-2003A patent/SK6392003A3/sk not_active Application Discontinuation
- 2001-10-25 CA CA002428519A patent/CA2428519A1/fr not_active Abandoned
- 2001-10-25 EP EP01996367A patent/EP1333821A2/fr not_active Withdrawn
- 2001-10-25 CZ CZ20031434A patent/CZ20031434A3/cs unknown
- 2001-11-14 AR ARP010105302A patent/AR035503A1/es not_active Application Discontinuation
2003
- 2003-05-13 NO NO20032149A patent/NO20032149D0/no not_active Application Discontinuation
- 2003-06-12 ZA ZA200304602A patent/ZA200304602B/en unknown

Also Published As

Publication number	Publication date
AU2002221744A1 (en)	2002-05-27
JP2004513915A (ja)	2004-05-13
WO2002039988A2 (fr)	2002-05-23
MXPA03004249A (es)	2003-09-22
US20040014788A1 (en)	2004-01-22
AR035503A1 (es)	2004-06-02
CA2428519A1 (fr)	2002-05-23
HUP0302761A2 (hu)	2003-12-29
ZA200304602B (en)	2004-09-13
BR0115297A (pt)	2003-08-26
RU2283648C2 (ru)	2006-09-20
PL361462A1 (en)	2004-10-04
NO20032149L (no)	2003-05-13
KR20030065511A (ko)	2003-08-06
NO20032149D0 (no)	2003-05-13
WO2002039988A3 (fr)	2002-07-25
CN1474688A (zh)	2004-02-11
EP1333821A2 (fr)	2003-08-13
CZ20031434A3 (cs)	2003-09-17

Legal Events

Date	Code	Title	Description
2010-12-07	FC9A	Refused patent application

Publication	Publication Date	Title
US20160058762A1 (en)	2016-03-03	Combinations of serotonin receptor agonists for treatment of movement disorders
EP1333832B1 (fr)	2007-11-28	Utilisations nouvelles d'agonistes 5-ht1a et d'inhibiteurs de recaptage de serotinine combines
AU2002215027A1 (en)	2002-08-01	Novel uses of combined 5-HT1A agonists and serotonin reuptake inhibitors
JP2007509896A (ja)	2007-04-19	β−３−アドレノセプターアゴニスト及びαアンタゴニスト及び／又は５−αレダクターゼインヒビターを含有する医薬組成物
AU2018333527A1 (en)	2020-03-05	Use of dried chicory root to protect poultry and livestock against ectoparasites or as insect repellant
SK6392003A3 (en)	2003-11-04	Novel uses of combined selective dopamine D2 receptor antagonists and 5-HT1A receptor agonists
US20060270677A1 (en)	2006-11-30	Method for the treatment of noise phobia in companion animals
CA2367444A1 (fr)	2000-09-21	Agents et procedes permettant de favoriser des gains de production animale
WO2012033874A1 (fr)	2012-03-15	Méthode de traitement de comportements auto-mutilants compulsifs
JP2005526713A (ja)	2005-09-08	慢性的疼痛、興奮毒性に関連した脳障害及び心臓不整脈の治療へのアンブロキソールの使用
Potter	1998	Clinical conditions of pigs in outdoor breeding herds
Sherman	2017	Keynote presentation: use of psychopharmacology to reduce anxiety and fear in dogs and cats: a practical approach
US20230413818A1 (en)	2023-12-28	Feed and methods for controlling tick infestations in a mammal
WO2015075003A1 (fr)	2015-05-28	Réduction de la douleur chez les animaux mâles pendant la castration
RU2024119390A (ru)	2024-08-19	Применение аминопиразольных соединений
Singh et al.	2008	Sustainable control of gastro-intestinal nematodes and lice infesting lambs
FR2619310A1 (fr)	1989-02-17	Compositions zootechniques renfermant du salbutamol